Drug intelligence / Profile preview

turkey herpesvirus, strain HVT-IBD-ND, expressing the VP2 protein of infectious bursal disease virus and the F protein of Newcastle disease virus, live recombinant

Development stage: Unknown
Lead developer: Zoetis
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous, In Ovo

Overview

**Poulvac Procerta HVT-IBD-ND** is a Zoetis live recombinant turkey herpesvirus vector vaccine for chickens and embryonated chicken eggs. The cell-associated HVT-IBD-ND vector expresses the VP2 antigen of infectious bursal disease virus and the fusion protein of Newcastle disease virus, while the HVT backbone provides protection against Marek's disease. It is indicated for active immunisation of one-day-old chicks or 18- to 19-day-old embryonated chicken eggs to reduce disease caused by Marek's disease virus, infectious bursal disease virus, and Newcastle disease virus. It is supplied as a frozen concentrate with solvent for suspension for injection and is administered subcutaneously or in ovo. ([ec.europa.eu](https://ec.europa.eu/health/documents/community-register/2025/20250123165022/anx_165022_en.pdf))

Brand names: Poulvac Procerta HVT-IBD-ND

Targets

HMPV F (Human metapneumovirus fusion protein)VP2 (Infectious bursal disease virus VP2 protein)

Beyond the preview

Go deeper on turkey herpesvirus, strain HVT-IBD-ND, expressing the VP2 protein of infectious bursal disease virus and the F protein of Newcastle disease virus, live recombinant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on turkey herpesvirus, strain HVT-IBD-ND, expressing the VP2 protein of infectious bursal disease virus and the F protein of Newcastle disease virus, live recombinant.

Explore the full profile